The Israeli government has ordered Médecins Sans Frontières (MSF) to cease operations in Gaza by the end of February, citing the aid group's refusal to hand over details of its Palestinian staff—a move critics decry as a dangerous politicization of humanitarian aid.
Israel announces a limited, security-heavy reopening of Gaza's Rafah crossing with Egypt, allowing some medical evacuations while concerns mount over aid access and the safety of returnees.
The U.S. Coast Guard has suspended its search for the crew of the fishing vessel Lily Jean after an extensive 24-hour operation. One unresponsive body and an empty life raft have been recovered, while six individuals are still missing at sea.
Human remains believed to be those of 19-year-old Matthew Packard-Asai have been found off Kahili Beach, ending a days-long search after he was pulled into the ocean by strong surf.
Tesla's stock is navigating turbulent waters, with a recent one-day surge contrasting sharply against a weaker quarterly performance. As the EV pioneer's share price hovers above some analyst targets, investors are left weighing its ambitious robotaxi and AI-driven future against more conservative valuation models.
Exelixis has filed its next-generation therapy zanzalintinib with U.S. regulators for metastatic colorectal cancer, marking a significant step in its clinical development and potentially enhancing its competitive position in the targeted oncology space.
In a rare firsthand account, Dr. Mohamed Ibrahim details his three-day escape from el-Fasher as paramilitary forces overran the city. His testimony paints a harrowing picture of urban warfare, civilian slaughter, and the systematic collapse of Sudan's last army bastion in Darfur.
Exclusive testimony from Dr. Mohamed Ibrahim, who fled the last hospital in Sudan's strategic el-Fasher, details a three-day ordeal of hiding from paramilitary forces, witnessing mass casualties, and surviving a kidnapping and ransom demand—shedding light on a siege the U.N. calls a 'massive crime scene.'
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
Gap's shares have soared over 100% in three years, fueled by a remarkable operational turnaround. But as the stock hovers near $28, investors are asking: does the current price fairly reflect the future, or has the market run ahead of itself? A deep dive into valuation metrics reveals a mixed picture.
Facing what its CEO calls one of the industry's toughest cycles, LyondellBasell reported weathering 2025 through aggressive cost control and working capital management. The chemical giant outlined a path to generate an additional $1.3 billion in cash by end-2026, even as it prepares to divest European assets and scales back circular economy spending.
JPMorgan raises Edison International's price target to $66, citing model updates ahead of earnings. The utility giant, noted for its sustainable high-yield dividend, continues to benefit from California's electrification trends and regulated investment framework.
Despite posting no revenue, Voltaic Strategic Resources (ASX:VSR) has seen its share price skyrocket 300% in the past year. We analyze whether its cash reserves can fuel further growth or if a reckoning is on the horizon.
While low-volatility stocks promise stability in turbulent markets, experts warn that their defensive appeal may mask underlying risks and missed opportunities for growth. We examine three such companies that investors might want to approach with caution.
While low-volatility stocks offer a haven in turbulent markets, their perceived safety can sometimes obscure underlying financial weaknesses. We examine three such stocks where calm trading patterns may not justify their current valuations or growth prospects.
Atlassian confronts a mounting identity theft campaign targeting its systems while rival Anthropic launches a competing AI collaboration tool, adding pressure to a stock already down over 50% in the past year.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Major music publishers have launched a massive copyright infringement lawsuit against AI company Anthropic, alleging its Claude AI was trained on a dataset of over 20,000 pirated songs, in a case that could redefine the rules for AI development.
France's maritime authority reports rescuing over 6,000 migrants from the English Channel last year, with at least 25 fatalities. Despite the peril, crossings persist at high volume, fueled by increasingly overcrowded boats and evolving smuggling methods.
Shares in Lloyds Banking Group have surged over 18% in three months, reigniting investor interest. As the stock hovers near analyst targets, a key question emerges: does the UK banking giant still offer value, or has the market run ahead of itself?
